Trodelvy® (sacituzumab govitecan-hziy) – New indication
February 3, 2023 - Gilead announced the FDA approval of Trodelvy (sacituzumab govitecan-hziy), for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Top